

Financial Tear Sheet

Corporate Profile

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid's drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in people with Angelman syndrome and completed a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.

Stock Performance

OVID (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	\$8.24
Change (%)	▲ 0.39 (4.97%)
Volume	15,481
52 Week High	\$15.93
52 Week Low	\$5.28
Market Cap	\$193,135,834
Rolling EPS	-2.65
PE Ratio	0
Shares Outstanding	24,603,291

Data as of March 22, 2018 12:40 p.m. ET



Recent Headlines

March 15, 2018

Ovid Therapeutics to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call on Thursday, March 29, 2018

March 15, 2018

Ovid Therapeutics Announces OV101 Granted Fast Track Designation by U.S. FDA for Treatment of Fragile X Syndrome

March 5, 2018

Ovid Therapeutics to Present at Two Upcoming Investor Conferences

SEC Filings

Filing Date

Form

February 13, 2018

SC 13G

January 24, 2018

8-K

January 23, 2018

4

January 23, 2018

4

Upcoming Events

Date

Title

March 23,
2018

10:00
a.m. ET

Ovid Therapeutics Inc at 25th Annual Future Leaders in the Biotech Industry

March 29,
2018

5:00
p.m. ET

Q4 2017 Ovid Therapeutics Inc Earnings Conference Call

April 21,
2018

through
April 27,
2018

Ovid Therapeutics Inc at the American Academy of Neurology 70th Annual Meeting

Corporate Governance

Jeremy Levin, D.Phil.,
MB BChir

Chairman of the
Board of
Directors

Data provided by Nasdaq. Minimum 15 minutes delayed.

© Ovid Therapeutics.. All rights reserved.